ArticleBMJ open2025

Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol.

Christine Brezden-Masley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.